JP2007529499A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007529499A5 JP2007529499A5 JP2007503433A JP2007503433A JP2007529499A5 JP 2007529499 A5 JP2007529499 A5 JP 2007529499A5 JP 2007503433 A JP2007503433 A JP 2007503433A JP 2007503433 A JP2007503433 A JP 2007503433A JP 2007529499 A5 JP2007529499 A5 JP 2007529499A5
- Authority
- JP
- Japan
- Prior art keywords
- asthma
- bronchitis
- bronchiectasis
- inhibitors
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 17
- 208000006673 asthma Diseases 0.000 claims 18
- 206010006451 bronchitis Diseases 0.000 claims 13
- 201000009267 bronchiectasis Diseases 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 229940044551 receptor antagonist Drugs 0.000 claims 5
- 239000002464 receptor antagonist Substances 0.000 claims 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- 230000001717 pathogenic effect Effects 0.000 claims 4
- 206010014561 Emphysema Diseases 0.000 claims 3
- 102000003141 Tachykinin Human genes 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 108060008037 tachykinin Proteins 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000000884 Airway Obstruction Diseases 0.000 claims 2
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 claims 2
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 208000007451 chronic bronchitis Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000024711 extrinsic asthma Diseases 0.000 claims 2
- 230000003325 follicular Effects 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 2
- 201000010659 intrinsic asthma Diseases 0.000 claims 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 2
- 230000000414 obstructive effect Effects 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims 2
- 102000004023 5-Lipoxygenase-Activating Proteins Human genes 0.000 claims 1
- 108090000411 5-Lipoxygenase-Activating Proteins Proteins 0.000 claims 1
- 229940122086 Adenosine A2a receptor agonist Drugs 0.000 claims 1
- 206010003557 Asthma exercise induced Diseases 0.000 claims 1
- 206010003645 Atopy Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 206010006482 Bronchospasm Diseases 0.000 claims 1
- 229940124638 COX inhibitor Drugs 0.000 claims 1
- 206010011416 Croup infectious Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000015554 Dopamine receptor Human genes 0.000 claims 1
- 108050004812 Dopamine receptor Proteins 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 229940122858 Elastase inhibitor Drugs 0.000 claims 1
- 208000004657 Exercise-Induced Asthma Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 229940122236 Histamine receptor antagonist Drugs 0.000 claims 1
- 239000003458 I kappa b kinase inhibitor Substances 0.000 claims 1
- 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 claims 1
- 102000042838 JAK family Human genes 0.000 claims 1
- 108091082332 JAK family Proteins 0.000 claims 1
- 102000005741 Metalloproteases Human genes 0.000 claims 1
- 108010006035 Metalloproteases Proteins 0.000 claims 1
- 229940122694 Muscarinic M3 receptor antagonist Drugs 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 229940123263 Phosphodiesterase 3 inhibitor Drugs 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 1
- 208000010362 Protozoan Infections Diseases 0.000 claims 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 claims 1
- 208000037656 Respiratory Sounds Diseases 0.000 claims 1
- 102000000551 Syk Kinase Human genes 0.000 claims 1
- 108010016672 Syk Kinase Proteins 0.000 claims 1
- 239000000150 Sympathomimetic Substances 0.000 claims 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 206010047924 Wheezing Diseases 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 239000002465 adenosine A2a receptor agonist Substances 0.000 claims 1
- 239000003470 adrenal cortex hormone Substances 0.000 claims 1
- 239000000533 adrenergic alpha-1 receptor agonist Substances 0.000 claims 1
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 claims 1
- 230000010085 airway hyperresponsiveness Effects 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 230000000954 anitussive effect Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 229940124584 antitussives Drugs 0.000 claims 1
- 210000000621 bronchi Anatomy 0.000 claims 1
- 230000007885 bronchoconstriction Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 201000009323 chronic eosinophilic pneumonia Diseases 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 229960000265 cromoglicic acid Drugs 0.000 claims 1
- 201000010549 croup Diseases 0.000 claims 1
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 239000000850 decongestant Substances 0.000 claims 1
- 229940124581 decongestants Drugs 0.000 claims 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 claims 1
- 239000003602 elastase inhibitor Substances 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 claims 1
- 208000024695 exercise-induced bronchoconstriction Diseases 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 239000000938 histamine H1 antagonist Substances 0.000 claims 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 claims 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 230000002427 irreversible effect Effects 0.000 claims 1
- 230000000155 isotopic effect Effects 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 230000000510 mucolytic effect Effects 0.000 claims 1
- 239000003681 muscarinic M3 receptor antagonist Substances 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 208000007892 occupational asthma Diseases 0.000 claims 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims 1
- 230000001991 pathophysiological effect Effects 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 claims 1
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 229940127230 sympathomimetic drug Drugs 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229960000278 theophylline Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229960005356 urokinase Drugs 0.000 claims 1
- 239000005526 vasoconstrictor agent Substances 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 3
- 238000003419 tautomerization reaction Methods 0.000 description 3
- 229930194542 Keto Natural products 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 125000003544 oxime group Chemical group 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04290724A EP1577292A1 (en) | 2004-03-17 | 2004-03-17 | Phenylaminoethanol derivatives as beta2 receptor agonists |
| US59185404P | 2004-07-27 | 2004-07-27 | |
| PCT/IB2005/000611 WO2005090288A1 (en) | 2004-03-17 | 2005-03-10 | Phenylaminoethanol derivates as beta2 receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007529499A JP2007529499A (ja) | 2007-10-25 |
| JP2007529499A5 true JP2007529499A5 (enExample) | 2008-04-03 |
Family
ID=34833790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007503433A Withdrawn JP2007529499A (ja) | 2004-03-17 | 2005-03-10 | β２受容体アゴニストとしてのフェニルアミノエタノール誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7482487B2 (enExample) |
| EP (2) | EP1577292A1 (enExample) |
| JP (1) | JP2007529499A (enExample) |
| BR (1) | BRPI0508724A (enExample) |
| CA (1) | CA2559533A1 (enExample) |
| WO (1) | WO2005090288A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200631929A (en) * | 2004-12-10 | 2006-09-16 | Speedel Experimenta Ag | ω -phenyloctanamides |
| RU2442771C2 (ru) | 2005-08-08 | 2012-02-20 | Арджента Дискавери Лтд | Производные бицикло[2,2,1]гепт-7-иламина и их применения |
| GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| WO2008002246A1 (en) * | 2006-06-28 | 2008-01-03 | Astrazeneca Ab | A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient. |
| JP5584138B2 (ja) | 2008-01-11 | 2014-09-03 | ノバルティス アーゲー | キナーゼ阻害剤としてのピリミジン類 |
| US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
| WO2010076553A1 (en) | 2008-12-30 | 2010-07-08 | Dr. Reddy's Laboratories Ltd | Sulfonamide compounds for the treatment of respiratory disorders |
| WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
| GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
| GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
| GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
| WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
| GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| JP5959541B2 (ja) | 2011-02-25 | 2016-08-02 | ノバルティス アーゲー | Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン |
| PT3691620T (pt) | 2017-10-05 | 2022-10-06 | Fulcrum Therapeutics Inc | Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1200886A (en) * | 1966-09-23 | 1970-08-05 | Allen & Hanburys Ltd | Phenylaminoethanol derivatives |
| US7268147B2 (en) * | 2003-05-15 | 2007-09-11 | Pfizer Inc | Compounds useful for the treatment of diseases |
-
2004
- 2004-03-17 EP EP04290724A patent/EP1577292A1/en not_active Withdrawn
-
2005
- 2005-03-10 WO PCT/IB2005/000611 patent/WO2005090288A1/en not_active Ceased
- 2005-03-10 EP EP05708707A patent/EP1727790A1/en not_active Withdrawn
- 2005-03-10 BR BRPI0508724-4A patent/BRPI0508724A/pt not_active IP Right Cessation
- 2005-03-10 CA CA002559533A patent/CA2559533A1/en not_active Abandoned
- 2005-03-10 JP JP2007503433A patent/JP2007529499A/ja not_active Withdrawn
- 2005-03-10 US US10/598,843 patent/US7482487B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007529499A5 (enExample) | ||
| JP2009530364A5 (enExample) | ||
| US9649302B2 (en) | Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast N-oxide | |
| JP4001542B2 (ja) | Ｎ−アルキル−アダマンチルトリアジニルベンズアミド誘導体 | |
| RU2009134512A (ru) | Гидрохлоридная соль 5-[3-(3-гидроксифенокси)азетедин-1-ил]-5-метил-2,2-дифенилгексанамида | |
| JP2006526613A5 (enExample) | ||
| JP2015535832A5 (enExample) | ||
| JP6120951B2 (ja) | 新規ｅｐ２受容体作動薬 | |
| ES2293530T3 (es) | Derivados de sulfonamidas para el tratamiento de enfermedades. | |
| JP2009534405A5 (enExample) | ||
| NO20054206L (no) | Bifenylderivater | |
| HRP20171296T1 (hr) | Derivati benzonitrila kao inhibitori kinaze | |
| JP2017531038A (ja) | 新規５，６−ジヒドロ−４Ｈ−ベンゾ［ｂ］チエノ−［２，３−ｄ］アゼピン誘導体 | |
| JP2012521994A5 (enExample) | ||
| WO2009126530A3 (en) | Piperidine derivatives as cgrp receptor antagonists | |
| RU2015121046A (ru) | Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов | |
| JP2011500621A5 (enExample) | ||
| KR20130094784A (ko) | 포스포디에스테라제 억제제를 포함하는 건조 분말 제제 | |
| JP2009526037A (ja) | トリアゾロピリジン化合物 | |
| JP2012523440A5 (enExample) | ||
| JP2007512237A5 (enExample) | ||
| JP2012505222A5 (enExample) | ||
| HRP20100035T1 (hr) | Kristalni oblici bifenilnog spoja | |
| CN114929700B (zh) | 三并环类pde3/pde4双重抑制剂化合物的药物组合物 | |
| JP2010507590A5 (enExample) |